- Home
- GLMD vs MBRX Comparison
GLMD vs MBRX Comparison
Compare GLMD & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLMD | MBRX |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.3M |
| IPO Year | 2013 | 2016 |
Fundamental Metrics
Financial Performance| Metric | GLMD | MBRX |
|---|---|---|
| Price | $4.37 | $0.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.00 |
| AVG Volume (30 Days) | 115.9K | ★ 2.1M |
| Earning Date | 05-21-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $0.16 |
| 52 Week High | $5.45 | $7.98 |
Technical Indicators
Market Signals| Indicator | GLMD | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 86.02 | 27.91 |
| Support Level | $0.56 | $0.26 |
| Resistance Level | N/A | $2.26 |
| Average True Range (ATR) | 0.19 | 0.07 |
| MACD | 0.45 | 0.07 |
| Stochastic Oscillator | 75.89 | 75.63 |
Price Performance
Historical ComparisonAbout GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.